Safety and efficacy of leflunomide in primary Sjogren's syndrome: a phase II pilot study
- 12 January 2007
- journal article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 66 (8), 1026-1032
- https://doi.org/10.1136/ard.2006.060905
Abstract
For invalidating symptoms in primary Sjögren's syndrome (pSS), there is still a need for easy-to-administer, cost-effective and well-tolerated systemic treatment. Leflunomide (LEF) is structurally unrelated to other immunomodulatory drugs and might be efficacious in pSS, given its characteristic immunoregulatory modes of action. To investigate the safety and efficacy of LEF in pSS in a phase II open-label pilot study. 15 patients with pSS with early and active disease received LEF 20 mg once daily for 24 weeks. Tolerability, safety and efficacy of LEF were evaluated every 8 weeks. Additional safety visits were performed every fortnight. Mild gastrointestinal discomfort (including diarrhoea) and hair loss were mainly reported. Five patients developed lupus-like skin lesions on the face, arms or trunk, responding well to topical corticosteroids, nevertheless causing the withdrawal of one patient. Two patients with pre-existing hypertension had to increase dosages of anti-hypertensive drugs. Increased levels of alanine aminotransferase normalised after dose reduction in two patients. A decrease in general fatigue and an increase in physical functioning were observed after 24 weeks. Serum IgG levels decreased from 8 weeks onwards. Schirmer test values increased, not reaching statistical significance, whereas sialometry values did not change. In four of five repeated biopsies, the lymphocytic focus score decreased at the rate of 1 focus/4 mm(2). A remarkable amelioration of leucocytoclastic vasculitis was observed in three patients. Although the safety profile seems fairly acceptable, the observed indications for efficacy were modest and may be doubtful in justifying a randomised controlled trial of LEF in pSS.Keywords
This publication has 39 references indexed in Scilit:
- Salivary gland and peripheral blood T helper 1 and 2 cell activity in Sjogren's syndrome compared with non-Sjogren's sicca syndromeAnnals Of The Rheumatic Diseases, 2005
- Leflunomide and Azathioprine Combination in Refractory Adult-Onset Still's DiseaseAnnals of Pharmacotherapy, 2005
- Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2005
- Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndromeArthritis Care & Research, 2004
- Etanercept in Sjögren's syndrome: A twelve‐week randomized, double‐blind, placebo‐controlled pilot clinical trialArthritis & Rheumatism, 2004
- Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double‐blind, randomized, placebo‐controlled clinical trialArthritis & Rheumatism, 2004
- Inefficacy of infliximab in primary Sjögren's syndrome: Results of the randomized, controlled trial of remicade in primary Sjögren's syndrome (TRIPSS)Arthritis & Rheumatism, 2004
- Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals Of The Rheumatic Diseases, 2002
- Leflunomide Suppresses TNF-Induced Cellular Responses: Effects on NF-κB, Activator Protein-1, c-Jun N-Terminal Protein Kinase, and ApoptosisThe Journal of Immunology, 2000
- Single-Blinded Controlled Trial of Low-Dose Oral IFN-α for the Treatment of Xerostomia in Patients with Sjögren's SyndromeJournal of Interferon & Cytokine Research, 1998